Correction to: Leukemia (2021) 36:1088–1101 https://doi.org/10.1038/s41375-021-01475-z, published online 27 January 2022
The Acknowledgments section of this article was incomplete in the initial publication. it should read as follows:
Acknowledgments: We thank Catherine A. Nicholas for her help with preliminary experiments and Morgan F. O’Keefe for manuscript proofreading. This work was supported by the National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707 and P01 CA155258; as well as by the Adelson Medical Research Foundation and the Paula and Rodger Riney Foundation.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Adamia, S., Bhatt, S., Wen, K. et al. Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia 36, 1700 (2022). https://doi.org/10.1038/s41375-022-01588-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-022-01588-z
